Profund Advisors LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Profund Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$38.96 - $42.75 $104,685 - $114,869	-2,687 Reduced 7.63%	32,547 $1.33 Million
Q1 2024 May 08, 2024	BUY	$40.88 - $43.27 $458,223 - $485,013	11,209 Added 46.66%	35,234 $1.49 Million
Q4 2023 Feb 14, 2024	SELL	$20.27 - $42.44 $201,868 - $422,659	-9,959 Reduced 29.3%	24,025 $1.02 Million
Q3 2023 Nov 13, 2023	BUY	$20.26 - $31.91 $27,938 - $44,003	1,379 Added 4.23%	33,984 $741,000
Q2 2023 Aug 10, 2023	SELL	$23.9 - $35.38 $160,392 - $237,435	-6,711 Reduced 17.07%	32,605 $1.04 Million
Q1 2023 May 11, 2023	BUY	$22.82 - $35.32 $897,191 - $1.39 Million	39,316 New	39,316 $958,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Profund Advisors LLC with notifications on news.